Dizal Pharmaceuticals

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to prior therapy. About 218 participants will be randomly assigned to receive either golidocitinib…

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is…

This study tests a new drug, DZD8586, combined with other treatments for people with diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults will join to see if the combination shrinks tumors and how safe it is. The goal is to better control the disea…

This study tests a new drug, DZD8586, against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to therapy. About 250 adults will be randomly assigned to receive either DZD8586 or a …

This study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. It is the first time this drug is being tested in humans. The main goals are to check the drug's safety and see if it can shrink tumors. About 190 adul…

This study tests a new two-drug combination (GW5282 and golidocitinib) for people with T-cell lymphoma, a rare blood cancer. The first part finds the safest dose, and the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed or relapsed di…

This early-stage study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene mutations. The main goals are to check the drug's safety and see if it can shrink tumors. About 140 adults will take part in this open-label study …

This study tests a new drug called DZD8586 in about 155 adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned, stopped responding to treatment, or caused unbearable side effects. The goal is to see if the drug can shrink or control the cancer and to…

This study tests an experimental drug called DZD8586 in adults with primary immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. About 60 participants will receive different doses to see if the drug safely raises platelet levels. The goal is to…